Many cancers evolve through early bursts of chromosome changes and originate from a single cancer cell
Researchers at The University of Texas MD Anderson Cancer Center found that genetically diverse cancer cells within tumors all originate from one common ancestral cell. According to a study published June 16, 2026, in Cancer Discovery, these tumors evolve through rapid bursts of genetic changes rather than gradual shifts, which helps explain how some cancers resist treatment.
Nicholas Navin, Ph.D., chair of Systems Biology, led the research. He stated that the findings provide a roadmap for developing smarter clinical diagnostic and treatment strategies to improve patient outcomes by revealing shared early genetic events and the bursts that drive diversity.
How do tumors evolve at the single-cell level?
Cancer cells do not evolve slowly. Instead, they grow through sudden bursts of rapid genetic changes known as copy number alterations (CNAs), which are gains or losses of entire DNA sections.
These bursts create a family tree of distinct subpopulations. These subgroups influence how aggressive a tumor becomes, its ability to metastasize, and how it responds to medical treatment.
Why does tumor diversity impact patient treatment?
Historically, doctors used bulk sequencing to analyze cancer genomes. This method blends cells together, which can mask minor cell populations.
Because tumors aren’t uniform, a single biopsy might miss important subpopulations. This omission could lead to treatments that are ineffective for the patient.
Single-cell sequencing allows researchers to see these hidden subpopulations. This approach may help guide predictive diagnostic strategies for patients with high genetic diversity in biomarker genes.
What are the markers of aggressive cancer growth?
The study analyzed over 62,000 aneuploid cells—cells with an abnormal number of chromosomes. Researchers found that TP53 mutations, genome doubling, and elevated CNA burden were frequent in many cancers.
These markers linked to chromosome loss and more aggressive disease. Tumors with higher genetic diversity also tended to form distinct spatial regions within the tissue.
To quantify this, researchers created the Punctuated Evolution Index (PEI). This index measures if genetic gains happen as a sudden burst or gradually. High PEI scores were associated with advanced disease stages and poorer clinical outcomes.
What happens next in tumor research?
These findings provide a framework for larger investigations. Future studies may include more patients and additional cancer types to further map tumor evolution.
This research could lead to more accurate diagnoses and personalized treatments. Such advancements are likely to improve overall clinical care and patient outcomes by accounting for intratumoral diversity.
Frequently Asked Questions
What is the Punctuated Evolution Index (PEI)?
The PEI is a tool created by researchers to quantify whether copy number alterations in a tumor occur as sudden, punctuated bursts or evolve gradually over time.
How many cells were analyzed in this study?
Researchers used single-cell sequencing on over 62,000 aneuploid cells from 94 tumors.
What is aneuploidy?
Aneuploidy occurs when a cell contains an abnormal number of chromosomes, which is a hallmark of tumors.
How could personalized diagnostics based on single-cell sequencing change the way you view cancer treatment?